Fighting the Drug Companies, for You; Call us toll-free at 1-877-917-5250.
warning: Parameter 2 to flowplayer3_swftools_flashvars() expected to be a reference, value given in /var/www/pressflow/includes/module.inc on line 450.
The use of transvaginal mesh for the treatment of stress urinary incontinence (SUI) and transvaginal repair of pelvic organ prolapse (POP) has been linked to serious complications including vaginal mesh erosion (also called exposure, extrusion or protrusion), pain (including painful sexual intercourse known as dyspareunia), infection, urinary problems, bleeding, and organ perforation.
On March 4, 2011, the FDA notified healthcare professionals and patients of an increased risk of development of cleft lip and/or cleft palate (oral clefts) in infants born to women treated with Topamax (topiramate) during pregnancy.
Accutane (generic: isotretinoin) has been linked to a variety of severe, life-threatening side effects including Birth Defects, Depression, Suicide, Inflammatory Bowel Disease (IBD), Crohn’s Disease, Ulcerative Colitis, and many others.
Health Canada announced on September 21, 2011 that Bayer resume sales of Trasylol. The company had suspended sales of Trasylol after evidence of a higher rate of death among Trasylol patients in a clinical study. Read more »
On August 16, 2011 the United States Judicial Panel on Multidistrict Litigation ordered that all pending federal cases involving injuries or deaths alleged to have been caused by the use of Darvocet, Darvon or generic Propoxyphene would be consolidated in MDL 2226. The Court accepted the defendants first choice of the Eastern District of Kentucky as site of the MDL. Read more »
A study published July 5, 2011, in the Archives of General Psychiatry, Antidepressant Use During Pregnancy and Childhood Autism Spectrum Disorders, reports that mothers exposed to SSRI antidepressants during pregnancy, such as Paxil, Zoloft or Prozac, have an increased of having a child born with autism.
Read more »
According to a market research study prepared by GlobalData, in 2009 DePuy held a 21% market share of the global hip and knee replacement market. This leads to the conclusion that as many 1 in 5 hip implant recipients have had DePuy devices installed and are now subject to the recall. Read more »
In an almost unprecedented joint announcement, the FDA and European regulators announced that access to Avandia, a medication to treat diabetes marketed by GlaxoSmithKline, will be severely restricted. Read more »